• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-01

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin conjugate for detecting accessible α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cells and tissues. It is appropriate for carbohydrate-focused immunofluorescence and flow cytometry workflows, but not for non-carbohydrate targets or assays that compromise the required divalent-ion environment.

• Stat3 in Fyn-Driven Dopaminergic Neurodegeneration

  2026-08-31

  This 2024 zebrafish study identifies Stat3 as a previously underappreciated downstream effector of hyperactive Fyn signaling in dopaminergic neuron loss and microglial inflammation. Its combination of cell-specific genetics, live imaging, transcriptomics, and pathway inhibition provides a practical framework for separating neuronal and inflammatory mechanisms in neurodegeneration research.

• Ibuprofen Toxicology and Biodegradation: Review Insights

  2026-08-31

  This review frames ibuprofen as an emerging contaminant by connecting widespread use, environmental persistence, organism-level toxicity, and incomplete removal in wastewater systems. Its central contribution is the evaluation of bacterial biodegradation as a promising but still insufficiently developed complement to conventional pharmaceutical-contaminant management.

• PPM1D, p38 MAPK, and Pyroptosis in Septic AKI

  2026-08-30

  The reference study identifies WIP1/PPM1D as a negative regulator of p38 MAPK–linked renal tubular pyroptosis in sepsis-associated acute kidney injury. By combining single-cell transcriptomic analysis, human tissue observations, HK2-cell experiments, and an LPS-induced mouse model, it shows that pharmacological PPM1D inhibition with CCT007093 intensifies inflammatory cell-death signaling in the kidney.

• IPR-803: Decoding uPAR Assay Evidence

  2026-08-29

  IPR-803 is a urokinase receptor inhibitor for dissecting uPAR–uPA-driven invasion, metastasis, and tumor-microenvironment biology. This evidence-centered guide distinguishes direct receptor blockade from formulation-dependent effects and translates the key literature into practical assay decisions.

• PRDX6–GPX4 Control of Ferroptosis

  2026-08-29

  Hu et al. identify PRDX6 as a dual regulator of ferroptosis resistance: it hydrolyzes peroxide phospholipids and promotes GPX4 relocation to membranes through a C47-dependent disulfide interaction. Inhibiting PRDX6 alongside ferroptosis inducers increases lipid peroxidation and suppresses liver and ovarian tumor models, providing a mechanistic framework for combination therapy.

• RG7388: An Assay-First MDM2 Antagonist Guide

  2026-08-28

  RG7388 is a selective MDM2 antagonist for restoring p53 signaling in wild-type p53 cancer models. This assay-first guide connects direct binding, functional apoptosis readouts, MDM1 biomarker biology, and translational combination-study design.

• (S)-Mephenytoin in Intestinal Organoid PK

  2026-08-28

  Use (S)-Mephenytoin as a mechanistically defined CYP2C19 substrate to benchmark oxidative metabolism in microsomes, intestinal epithelial cells, and hiPSC-derived organoid workflows. This guide connects enzyme kinetics with practical exposure design, metabolite tracking, and troubleshooting for more human-relevant pharmacokinetic studies.

• Rucaparib (AG-014699) DNA Repair Assay Guide

  2026-08-27

  Rucaparib (AG-014699) gives researchers a practical PARP1 perturbation tool for linking DNA damage, radiation response, and repair-pathway defects. This workflow extends beyond standard viability assays by combining clonogenic survival, γ-H2AX or p53BP1 imaging, and spliceosome-informed biomarker analysis.

• Chronic Cabozantinib Adaptation in RCC

  2026-08-27

  This study uses quantitative phosphoproteomics to distinguish acute from chronic signaling remodeling after Cabozantinib exposure in renal cell carcinoma. Its central finding is that long-term adaptation preserves MET activation-loop suppression while selectively reshaping adhesion-, stress-, and MAPK/AP-1-associated phosphorylation programs linked to modest changes in cellular motility.

• HyperFluor 488: A Better Human IgG Assay Strategy

  2026-08-26

  Learn how the HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody converts human IgG binding into a sensitive fluorescence readout. This article connects rational SARS-CoV-2 vaccine evaluation with practical decisions for assay controls, species compatibility, multiplexing, and reproducibility.

• Pronase E for TNBC Proteomics Workflows

  2026-08-26

  Pronase E is a high-activity protease mixture for broad protein digestion, limited proteolysis, and mechanism-focused sample preparation. This article translates the CUL3–MTDH ferroptosis findings in triple-negative breast cancer into practical assay design, optimization, and troubleshooting strategies.

• HIV-1 Nuclear Pores and Resting T-Cell Infection

  2026-08-25

  The reference study identifies nuclear pore complex remodeling as a decisive bottleneck in HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates CD4–LCK–CDK1 signaling, phosphorylates nucleoporins, and enables capsid nuclear import without requiring cell-cycle entry.

• LSE Platforms for Spatiotemporal mRNA Delivery

  2026-08-25

  The reference study develops a lipid nanoparticle-stabilized emulsion (LSE) that redirects mRNA delivery toward antigen-presenting cells and improves the durability and breadth of T cell responses in mice. Its findings suggest that controlling where and when antigen is expressed may be as important as increasing total mRNA expression, although translation beyond preclinical models remains unresolved.

• Thioredoxin 1 and Lens Iron Metabolism in Oxidative Damage

  2026-08-24

  This preprint identifies thioredoxin 1 (Trx1) as a possible regulator of late-stage recovery from oxidative damage and iron dysregulation in the lens, with ferritin heavy chain (FTH1) implicated as a downstream mediator. Its staged in vivo and in vitro design emphasizes that age-related cataract biology may change over time, although the proposed Trx1–FTH1 mechanism requires validation in peer-reviewed and clinically relevant models.

451 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page